Zhimeng Biotechnology

Overview

Zhimeng Biotechnology is a Chinese biopharmaceutical company focused on developing innovative small molecule therapeutics targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and related innate immune pathways. Based in Shanghai, the company leverages China's growing expertise in drug discovery and global partnerships to advance its pipeline of NLRP3 inhibitors for neurodegenerative and inflammatory diseases.

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2018 |
| Headquarters | Shanghai, China |
| CEO | Dr. Wei Zhang |
| Funding | Series B ($40M, 2023) |
| Focus | NLRP3 inhibitors, innate immunity |
| Stage | Preclinical/IND-enabling |

Business Model

Zhimeng operates with a hybrid model:

Internal discovery: Proprietary small molecule library and screening platform

Academic partnerships: Collaborations with Chinese universities and research institutes

Global licensing: Out-licensing of programs to global partners for major markets

Science and Technology

NLRP3 Platform

Zhimeng's NLRP3 program is built on:

• High-throughput screening: Automated screening of compound libraries
• Structure-activity relationship (SAR): Rapid optimization of lead compounds
• In vivo pharmacology: Robust PD models including MPTP and 6-OHDA

Approach

The company focuses on developing next-generation NLRP3 inhibitors with:

...

Overview

Zhimeng Biotechnology is a Chinese biopharmaceutical company focused on developing innovative small molecule therapeutics targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and related innate immune pathways. Based in Shanghai, the company leverages China's growing expertise in drug discovery and global partnerships to advance its pipeline of NLRP3 inhibitors for neurodegenerative and inflammatory diseases.

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2018 |
| Headquarters | Shanghai, China |
| CEO | Dr. Wei Zhang |
| Funding | Series B ($40M, 2023) |
| Focus | NLRP3 inhibitors, innate immunity |
| Stage | Preclinical/IND-enabling |

Business Model

Zhimeng operates with a hybrid model:

Internal discovery: Proprietary small molecule library and screening platform

Academic partnerships: Collaborations with Chinese universities and research institutes

Global licensing: Out-licensing of programs to global partners for major markets

Science and Technology

NLRP3 Platform

Zhimeng's NLRP3 program is built on:

• High-throughput screening: Automated screening of compound libraries
• Structure-activity relationship (SAR): Rapid optimization of lead compounds
• In vivo pharmacology: Robust PD models including MPTP and 6-OHDA

Approach

The company focuses on developing next-generation NLRP3 inhibitors with:

Enhanced BBB penetration: Optimized for CNS indications

Improved pharmacokinetics: Once-daily oral dosing

Reduced off-target effects: High selectivity for NLRP3

Pipeline

Programs

| Program | Mechanism | Indication | Stage | Status |
|---------|-----------|------------|-------|--------|
| ZM-001 | NLRP3 inhibitor | Parkinson's disease | Preclinical | IND-enabling |
| ZM-002 | NLRP3 inhibitor | Osteoarthritis | Preclinical | Lead optimization |
| ZM-003 | NLRP3/TNFR dual | Inflammatory bowel disease | Discovery | Early stage |

ZM-001 (Parkinson's Disease)

ZM-001 is Zhimeng's lead program for Parkinson's disease:

• Mechanism: Direct NLRP3 inhibition (NACHT domain binding)
• Potency: IC50 < 100 nM in cell-based assays
• BBB penetration: Brain-to-plasma ratio >0.4
• Efficacy: >50% neuroprotection in MPTP mouse model

The company has completed GLP toxicology studies and plans to file IND in 2025.

ZM-002 (Osteoarthritis)

ZM-002 targets peripheral inflammation in osteoarthritis:

• Mechanism: Same as ZM-001 but optimized for peripheral exposure
• Advantage: Lower brain exposure, reduced CNS side effects
• Status: Phase 1 planned for 2025

Academic Partnerships

Zhimeng has established partnerships with leading Chinese research institutions:

• Shanghai Institute of Materia Medica (SIMM): Natural product screening
• Fudan University: NLRP3 biology and animal models
• Chinese Academy of Sciences: Structural biology

Global Strategy

Zhimeng's strategy includes:

China market: Independent development and commercialization

Global partnerships: Out-license to major pharma for US/EU/Japan

Regional hubs: Establish R&D presence in Boston and Basel

Funding

| Round | Amount | Year | Investors |
|-------|--------|------|-----------|
| Series A | $12M | 2019 | Hillhouse Capital, Qiming Venture |
| Series B | $40M | 2023 | Hillhouse Capital, Legend Capital |

Competitive Position

Zhimeng represents China's entry into the NLRP3 inhibitor space:

| Company | Location | Strength |
|---------|----------|----------|
| Zhimeng | China | Cost-effective R&D, large patient pool |
| Olacteant | US | Clinical data |
| NodThera | UK | CNS expertise |
| Ventus | US | Dual-target platform |
| IFM/BMS | US | Big pharma resources |

Development Timeline

gantt
title Zhimeng Biotechnology PD Program
dateFormat YYYY
axisFormat %Y

section ZM-001
Discovery :done, 2019, 2021
Lead optimization :done, 2021, 2023
IND-enabling :active, 2023, 2025
IND filing :2025, 2025
Phase 1 :2025, 2026

References

[Zhimeng Biotechnology](https://www.zhimengbiotech.com)

[NLRP3 and alpha-synuclein (2021)](https://pubmed.ncbi.nlm.nih.gov/34545678/)

See Also

• [NLRP3 Inflammasome Inhibitors for Parkinson's Disease](/mechanisms/nlrp3-inflammasome-inhibitors-parkinsons)
• [NodThera Ltd.](/companies/nodthera)
• [Chinese neurodegeneration Biotech](/companies/brazilian-neurodegeneration-biotech)
• [NLRP3 Inhibitors Investment Landscape](/investment/nlrp3-inflammasome)